METTL16 and neoplasm: These findings suggest that METTL16 functions not only as a potential prognostic biomarker but also as a tumor suppressor “writer” in PDA, influencing the TME and antitumor immune responses and highlighting its potential as an immunotherapeutic target (Figure 4).